XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Nature of Business - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Nov. 01, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Cash, cash equivalents and short-term investments   $ 14,600           $ 14,600    
Net Income (Loss)   (5,618) $ (3,954) $ 130 $ (4,619) $ (6,304) $ (19,288) (9,442) $ (30,211)  
Accumulated deficit   (155,506)           (155,506)   $ (146,064)
Consideration Transferred               29,400    
Total operating expenses   $ 5,736     $ 4,833     18,032 $ 33,756  
Private Placement                    
Gross proceeds from the private placement               20,400    
Net proceeds from private placement               19,000    
Commissions and other transaction expenses               $ 1,400    
Stock issued               20,700,000    
Subsequent Event [Member]                    
Proceeds from issuance Initial Public Offering $ 10,200                  
Subsequent Event [Member] | Public Offering                    
Shares issued, price per share $ 3.75                  
Proceeds from issuance Initial Public Offering $ 10,200                  
Underwriters option period 30 days                  
Maximum number of additional shares issued 408,000                  
CalciMedica                    
Percentage of ownership of common stock   72.00%           72.00%    
Graybug                    
Percentage of ownership of common stock   28.00%           28.00%    
Convertible Debt [Member]                    
Proceeds from issuance of convertible notes               $ 8,600    
Common Stock [Member]                    
Stock issued     8,950         101,522    
Common Stock [Member] | Subsequent Event [Member] | Public Offering                    
Stock issued 2,720,000                  
Maximum number of additional shares issued 408,000                  
Preferred and Common stock [Member]                    
Total net proceeds               $ 131,700